# Broncus Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/broncus-medical

- Industry: Medical Devices & Equipment
- Headquarters: San Jose, US
- Website: www.broncus.com
- Total disclosed funding: $103M
- Latest round: Series D (Jan 28, 2021)
- Investors on record: 29

## About

Founded in 1997 and based in California, US, Broncus Medical, Inc. develops and commercializes medical devices to treat patients with lung diseases. The company was founded by Glen French and in September 2021, Broncus Medical, Inc. raised HKD 1.55 billion in an IPO (initial public offering) at HKD 18.7 per share on the HKSE (Hong Kong Stock Exchange). 

The company develops various medical devices such as LungPoint Virtual Bronchoscopic Navigation Systems, an image-guided device that helps physicians to plan bronchoscopic procedures and navigate tumors in the lungs. An 18 gauge coring needle called FleXNeedle is used for peripheral sampling and access to inaccessible areas of the lungs. Broncus Medical, Inc. also offers Archimedes System, a platform that utilizes BTPNA (Bronchoscopic Trans-Parenchymal Nodule Access) for nodule, vessel mapping, airway mapping, pathway guidance, and intra-operative fluoroscopy imaging.

The company generated a revenue of USD 8.072 million in 2019 and USD 3.259 million in 2020.

Broncus Medical, Inc. plans to boost its research and development efforts and commercialize its products.

## Funding rounds

- Series D, Jan 28, 2021 — FountainVest, Summer Capital, Exome Asset Management, Valliance Capital
- Series C, Sep 28, 2020 — Qiming Venture Partners, Baidu Capital, DCP Capital, CNCB (Hong Kong) Investment, Lake Bleu Capital, Ascendum Capital
- Series G, Dec 3, 2008, $38M — Abingworth, Focus Ventures, Menlo Ventures, HBM Partners, Saints Capital, Pac-Link, SightLine Partners, SG Growth Capital, Ares Life Sciences
- Series F, Aug 30, 2006, $30M — Abingworth, Menlo Ventures, HBM Partners, Japan Asia Investment Company, BioStar Capital, Pac-Link, SightLine Partners, Saratoga Ventures, Rockport Venture Partners, Biomedical Sciences Investment Fund
- Series E, Sep 1, 2004, $8.8M — Menlo Ventures, HBM Partners, SightLine Partners, Boston Scientific Corporation
- Series E, Mar 17, 2004, $7M — Menlo Ventures, Oakwood Medical Investors, FirstMark Capital, Sightline Payments LLC
- Series D, Apr 26, 2002, $20M — Boston Scientific Ventures

## Investors

- Boston Scientific Ventures (https://capitalatlas.ai/funds/boston-scientific-ventures) — Series D
- Menlo Ventures (https://capitalatlas.ai/funds/menlo-ventures) — Series E, Series F, Series G
- Oakwood Medical Investors (https://capitalatlas.ai/funds/oakwood-medical-investors) — Series E
- FirstMark Capital (https://capitalatlas.ai/funds/firstmark-capital) — Series E
- Sightline Payments LLC — Series E
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series E, Series F, Series G
- SightLine Partners — Series E, Series F, Series G
- Boston Scientific Corporation — Series E
- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series F, Series G
- Japan Asia Investment Company (https://capitalatlas.ai/funds/japan-asia-investment-company) — Series F
- BioStar Capital (https://capitalatlas.ai/funds/biostar-capital) — Series F
- Pac-Link (https://capitalatlas.ai/funds/pac-link) — Series F, Series G
- Saratoga Ventures (https://capitalatlas.ai/funds/saratoga-ventures) — Series F
- Rockport Venture Partners — Series F
- Biomedical Sciences Investment Fund — Series F
- Focus Ventures (https://capitalatlas.ai/funds/focus-ventures) — Series G
- Saints Capital (https://capitalatlas.ai/funds/saints-capital) — Series G
- SG Growth Capital (https://capitalatlas.ai/funds/sg-growth-capital) — Series G
- Ares Life Sciences (https://capitalatlas.ai/funds/ares-life-sciences) — Series G
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series C
- Baidu Capital (https://capitalatlas.ai/funds/baidu-capital) — Series C
- DCP Capital (https://capitalatlas.ai/funds/dcp-capital) — Series C
- CNCB (Hong Kong) Investment (https://capitalatlas.ai/funds/cncb-hong-kong-investment) — Series C
- Lake Bleu Capital (https://capitalatlas.ai/funds/lake-bleu-capital) — Series C
- Ascendum Capital (https://capitalatlas.ai/funds/ascendum-capital) — Series C
- FountainVest (https://capitalatlas.ai/funds/fountainvest) — Series D
- Summer Capital — Series D
- Exome Asset Management — Series D
- Valliance Capital — Series D